For the diabetes indication, Eli Lilly launched tirzepatide under brand name Mounjaro (27% market share), a once-weekly injection that activates receptors for two hormones in the body that are critical for appetite regulation and glycemic control, gastric inhibitory polypeptide (GIP), and glucagon-like peptide-1 (GLP-1)
(ii) major medical problems, including cardiac, liver, endocrine or renal disease
Lasers like the Lumenis UltraPulse Encore CO2 laser and the Sciton Erbium:YAG laser offer fractional resurfacing and are excellent at treating deeper wrinkles and severe textural issues from weight loss
This is what Kennedy has called the war on peptides. In explaining its decisions, the FDA pointed to well-established research in peptide drug development that injectable peptides carry the risk of causing immune reactions
And honestly I get why
Meanwhile, giants like Roche ($73.3B), Pfizer ($62.6B), and AstraZeneca ($58.7B) are expanding their footprint through diagnostics, pipeline oral GLP-1 agonists, and SGLT2 inhibitors respectively
